Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.
<h4>Background</h4> <p>Vedolizumab specifically recognizes the 47 integrin and selectively blocks gut lymphocyte trafficking: potentially, it offers gut-specific immunosuppression. </p> <h4>Aims</h4> <p>To review the safety of vedolizumab and summarise p...
| मुख्य लेखकों: | , , |
|---|---|
| स्वरूप: | Journal article |
| भाषा: | English |
| प्रकाशित: |
Wiley
2017
|